Navigation Links
SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases

SAN DIEGO and MCLEAN, Va., Nov. 1 /PRNewswire-FirstCall/ -- Science Applications International Corporation (NYSE: SAI) today announced that it was awarded a contract extension by the National Institute of Allergy and Infectious Diseases' (NIAID) Division of Microbiology and Infectious Diseases (DMID), part of the National Institutes of Health, to provide malaria vaccine production and support services.

The seven-year cost-plus-fixed-fee contract has an estimated value of $32.7 million. The contract extension represents a follow-on effort for previous work SAIC has been performing for NIAID since 2000.

The SAIC-led team will deliver research and development services to support process development and pilot lot production of promising malaria vaccine candidates into products suitable for evaluation in human clinical studies. SAIC will serve as the project management arm for these activities, helping to identify optimal production and purification strategies for clinical-grade malaria immunogens, performing pilot lot production, formulation, preclinical testing, and providing nonclinical development support for promising vaccine candidates. SAIC will also provide regulatory support for investigational new drug applications.

"SAIC is honored that NIAID has selected us to continue to support the development and characterization of malaria vaccine candidates," said Robert McCord, SAIC business unit general manager. "Our life sciences team is dedicated to the search for a viable vaccine for this disease, which kills more than one million infants, young children and pregnant women every year."

SAIC is a leading provider of scientific, engineering, systems integration and technical services and solutions to all branches of the U.S. military, agencies of the Department of Defense, the intelligence community, the U.S. Department of Homeland Security and other U.S. Government civil agencies, as well as to customers in selected commercial markets. With more than 44,000 employees in over 150 cities worldwide, SAIC engineers and scientists solve complex technical challenges requiring innovative solutions for customers' mission-critical functions. SAIC had annual revenues of $8.3 billion for its fiscal year ended January 31, 2007.


Statements in this announcement other than historical data and information constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements or industry results to be very different from the results, performance or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in SAIC's Annual Report on Form 10-K for the period ended January 31, 2007, and such other filings that SAIC makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

Contact: Melissa Koskovich, McLean Ron Zollars, San Diego

703/676-6762 858/826-7896

Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Vastox Awarded £400,000 Grant to Support R&D at Carbohydrate Chemistry Facility
2. Use of Sequenoms MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
5. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
6. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
7. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
10. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
11. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... November 26, 2015 --> ... use SyMRI to find optimal contrast weighting of MRI ... and has signed a research agreement with SyntheticMR in order ... Using SyMRI, it is possible to generate multiple contrast images ... the patient has left, thus making it possible to both ...
(Date:11/26/2015)... , November 26, 2015 3D ... by 2022, according to a new report by Grand View ... Kidney Disease (CKD) which demands kidney transplantation is expected to ... cost effective substitute for organ transplantation. --> 3D ... by 2022, according to a new report by Grand View ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back ... to choose from, the possibilities are endless. Users have full control over angle of ... Pulse masking effects, users are sure to get heads to turn. , ProPanel: Pulse ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Toronto and the University of British Columbia suggested that laws requiring bicyclists to wear ... explains that part of the reason for the controversial conclusion is that, while helmets ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... ... ... Herpes-only dating community in the world, revealed that over 50% of its members are under ... under the age of 50 – or 67% of the population - are infected with ... infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of the ...
Breaking Medicine News(10 mins):